The interaction of the investigational HCV protease inhibitors VX-950 and SCH 503034 with ritonavir, a potent inhibitor of cytochrome P450 3A, was studied in vitro and in vivo. In rat and human liver microsomes, the metabolism of VX-950 and SCH 503034 was strongly inhibited by the presence of 4 μM ritonavir. Upon co-dosing either VX-950 or SCH 503034 with ritonavir in rats, plasma exposure of the HCV protease inhibitors was increased by >15-fold, and plasma concentrations 8 h after dosing were increased by >50-fold. A human pharmacokinetic model of VX-950 co-administered with low-dose ritonavir suggested that improved efficacy and/or dosing convenience may be feasible by pharmacokinetic enhancement with ritonavir.
Current standard of care for the treatment of hepatitis C virus (HCV) infection consists of combination regimens with pegylated interferon (peg-IFN)-α and ribavirin. This therapy is poorly tolerated and not highly efficacious, particularly in patients infected with HCV genotypes 1 and 4-6. Therefore, there is intense interest in the development of orally active, small-molecule inhibitors of HCV replication that may offer enhanced efficacy. In short-term clinical studies, inhibitors of the HCV NS3 protease have demonstrated marked antiviral activity, lowering plasma HCV RNA, the principal biomarker of HCV replication in vivo, by several orders of magnitude (Lamarre et al., 2003) . Two HCV protease inhibitors (PIs), VX-950 (Perni et al., 2006) and SCH 503034 , are currently being assessed in combination with peg-IFN in Phase II clinical studies. Although demonstrating substantial antiviral activity, both compounds are relatively rapidly cleared and must be dosed three times daily to maintain sufficient plasma trough concentrations (C trough ), which have been correlated with potency in vivo.
Structurally, HCV PIs resemble the peptidomimetic inhibitors of human immunodeficiency virus (HIV) protease.
HIV PIs also show high clearance, and plasma trough levels correlate with antiviral activity in antiretroviral-experienced patients. However, since HIV PIs are primarily or exclusively metabolized by the cytochrome P450 (CYP) 3A system, their plasma levels are markedly enhanced and prolonged by co-dosing with ritonavir, a potent CYP3A inhibitor (Kempf et al., 1997; King et al., 2004) . The pharmacokinetic boosting of HIV PIs with ritonavir increases antiviral efficacy, allows twice-or once-daily dosing, and delays or prevents the emergence of drug resistance (Kempf et al., 2004; Shulman et al., 2002) . To assess the potential to enhance VX-950 and SCH 503034 plasma levels, we evaluated their interactions with ritonavir in preclinical metabolism and pharmacokinetic models. These models were used to predict the interaction of VX-950 with ritonavir in humans.
VX-950 and SCH 503034 were added to rat or pooled human liver microsomes (RLM and HLM, respectively). After activation with NADPH, in vitro oxidative metabolism was measured by monitoring the disappearance of parent compound over 30 min. The HIV PI lopinavir, which is rapidly metabolized by CYP3A and substantially boosted by ritonavir co-dosing (Sham et al., 1998) , was used as a positive control. Greater than 99% disappearance of lopinavir was observed within 30 min in both RLM and HLM ( Table 1) . Addition of 0.4 μM ritonavir substantially inhibited this metabolism. The HCV PIs VX-950 and SCH 503034 were less rapidly metabolized in vitro than lopinavir; however, approximately 40-80% metabolism of parent drug was observed over 30 min. Substantial inhibition by 0.4 μM ritonavir was observed, and in the presence of 4 μM ritonavir, metabolism of both VX-950 and SCH 503034 was completely inhibited in both rat and human systems.
The inhibition of VX-950 and SCH 503034 metabolism in vitro by ritonavir suggested that, like lopinavir and other HIV PIs, the plasma levels of these HCV PIs might be pharmacokinetically enhanced by co-dosing with ritonavir. VX-950 and SCH 503034 were dosed intravenously and orally at 5 mg/kg to male Sprague-Dawley rats. A third group of rats received either VX-950 or SCH 503034 orally along with a 5 mg/kg co-dose of ritonavir. In the absence of ritonavir, both compounds were rapidly cleared after IV administration (mean CLp 1.7 and 2.0 l/h/kg, respectively) with plasma half-life of <0.5 h ( Table 2) . Plasma levels of VX-950 following oral dosing were higher than those of SCH 503034, but both compounds produced relatively low plasma exposure and low to modest bioavailability. As shown in Figure 1 , both HCV PIs were markedly boosted by ritonavir co-dosing. Plasma exposure (area under the curve [AUC] 0-8h ) to VX-950 and SCH 503034 increased by >15-fold to 18.6 and 2.18 μg h/ml, respectively, and peak concentration (C max ) of both compounds increased by >threefold (Table 2) . Most notably, concentrations of both compounds 8 h after dosing increased by >50-fold.
To model the interaction between VX-950 and ritonavir in humans, the concentration dependence of inhibition in human liver microsomes was assessed. The inhibition constant (K i ) for ritonavir for inhibition of VX-950 metabolism was determined by Dixon plot and estimated to be 0.321 μg/ml in vivo (data not shown). Using methodology originally developed for the pharmacokinetic enhancement of lopinavir by ritonavir , a human pharmacokinetic model of ritonavir-boosted VX-950 was constructed based on this K i , the human pharmacokinetic parameters for VX-950 (apparant oral clearance [CL 0 ]=41 l/h, volume of distribution [V ]=230 l, absorption rate constant [K a ]=0.624 h -1 ) (Chu et al., 2005) and ritonavir (CL 0 =10.1 l/h, V=114 l) , and the conservative assumption that ritonavir will increase the bioavailability of VX-950 by 100% (a threefold increase was observed in rats). As shown in Figure 2 , twice-daily dosing of VX-950/ritonavir at 250/100 mg is predicted to provide a mean plasma C trough equivalent to that achieved with VX-950 750 mg every 8 h. Increasing the dose of VX-950/ritonavir to 500/100 mg twice daily is predicted to more than double the plasma C trough , albeit with substantially (2 mM) were prepared in 50 mM phosphate buffer at pH 7.4. Stock solutions (10 mM) of test compound were prepared in DMSO and then diluted to 100 μM in 1:1 acetonitrile/water. The solutions of compounds were added into the NADPH cofactor solution containing 0, 0.8 or 8 μM of ritonavir in a 2 ml 96-well plate. The resulting solution was added to the microsomes (1:1) that had been pre-incubated for 10 min at 37˚C. Samples (0.1 ml) were incubated in 96-well plates at 37°C for 0, 10, 20 and 30 min in a Tecan 4-slot incubator (Tecan US). At each time point, the robotic arm removed one of the replicate plates and the reactions were stopped by adding 1 volume (100 μl) of acetonitrile with internal standard (0.05 µM buspirone) to each well. All plates were centrifuged at 3,500 rpm for 30 min, and the supernatant was transferred to a 96-well injection plate. The plates were stored at 4°C until LC-MS/MS analysis. The samples were analysed in positive mode using the turbospray ion source of PE/Sciex API 4000 Q-Trap mass spectrometer (Applied Biosystems, Foster City, CA, USA) with Shimadzu (Koyoto, Japan) HPLC system. Samples were injected (5 μl) onto a Lancer C18 column (5 μm, 30x2.1 mm) from Analytical Sales and Services Inc. (Pompton Plains, NJ, USA) and separation occurred via a gradient. The flow rate was 0.5 ml/min; starting conditions of 7.5% B, 2.5% C, increasing to 30% B and 10 % C at 0.4 min and held for 0.4 min. The percentage of B and C were rapidly increased to 74% and 21%, respectively, over 0.5 min and held for 0.7 min, then decreased back to the initial conditions over 0.1 min, and held for 0.4 min, for a total run time of 2.5 min. Mobile phase A was 95/5 water/methanol (v/v) with 10 mM ammonium acetate and 60 μl/l acetic acid. Mobile phase B was methanol containing 10 mM ammonium acetate and 60 μl/l acetic acid. Mobile phase C was acetonitrile. Table 1 . Inhibition of the metabolism of VX-950 and SCH 503034 by ritonavir in rat and human liver microsomes* higher C max of VX-950. The sensitivity of plasma C trough to the effect of ritonavir on VX-950 bioavailability was also explored (data not shown). If bioavailability is increased by less than 100%, plasma C trough appears to be enhanced primarily through ritonavir-mediated inhibition of terminal elimination. If bioavailability is increased by more than twofold, further reduction in VX-950 doses may be feasible. Sensitivity analyses were further performed with various fractions of VX-950 clearance attributed to CYP3A and resulting ritonavir-mediated inhibition. If CYP3A contributes to only half of total VX-950 clearance, the plasma C trough is predicted to be above those achieved with 750 mg thrice daily for doses as low as 450 mg twice daily when co-administered with ritonavir. ) received a 5 mg/kg intravenous or oral dose of either VX-950 or SCH 503034, administered alone, or a 5 mg/kg oral dose in combination with a 5 mg/kg oral dose of ritonavir. All compounds were administered as 5 mg/ml solutions in a 10% DMSO: 90% PEG-400 vehicle as a slow bolus (~1 min) in a jugular vein under isoflurane anesthetic (IV) or by gavage (oral). Serial blood samples were obtained from a tail vein of each animal 0.1 (IV only), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 h after dosing. The heparinized samples were placed on ice immediately following collection. Plasma was separated by centrifugation and stored frozen for subsequent analysis. Following liquid-liquid extraction of the plasma samples, concentrations of parent drug (and ritonavir) were determined by HPLC-MS/MS. Analysis was performed on a Sciex API 2000™ Biomolecular Mass Analyzer (Applied Biosystems, Foster City, CA, USA) using Turbo Ion Spray. Peak areas of the title compounds and internal standards were determined using the Sciex MacQuan™ software (Applied Biosystems). Calibration curves were derived from peak area ratio (parent drug/internal standard) of the spiked plasma standards using least squares linear regression of the ratio versus the theoretical concentration. The plasma concentration data were submitted to multiexponential curve fitting using WinNonlin. The area under the curve (AUC) 0-8h was calculated using the linear trapezoidal rule for the plasma-time profiles. The apparent total plasma clearance (CL p ) was calculated by dividing the administered dose by the AUC. The bioavailability (F) was calculated as the dose-normalized AUC from the oral dose divided by the corresponding value derived from an intravenous dose. C max , plasma peak concentration; C 8 h , plasma concentration at 8 h; N.D., not detected; t 1/2 , elimination half-life;V ss , steady-state volume; V β , distribution volume These findings suggest that the rapid clearance of both VX-950 and SCH 503034 in humans is primarily the result of oxidative metabolism by CYP3A, since even low (0.4 μM) concentrations of ritonavir largely inhibited metabolism in HLM. The similarity between RLM and HLM in both disappearance rates and inhibition by ritonavir, combined with the large increase in plasma concentrations in rats also suggests that VX-950 and SCH 503034 will be substantially boosted by co-dosing with ritonavir in humans. More detailed analysis of the in vitro interaction of VX-950 and ritonavir, resulting in the above simulated human pharmacokinetic (PK) model, supports this assertion, predicting that VX-950 should be able to be dosed twice daily by co-administration of low-dose (100 mg) ritonavir.
The similarities between the pharmacokinetic/pharmacodynamic relationships of HCV and HIV PIs suggest that ritonavir boosting may substantially improve the therapeutic use of HCV PIs such as VX-950 and SCH 503034. In preliminary monotherapy studies, the antiviral activity (as measured by decline in plasma HCV RNA from baseline) of both of these HCV PIs has been correlated to plasma C trough levels (Chu et al., 2005 . Indeed, studies with VX-950 have been conducted with strict 8-h dosing (rather than thrice daily) dosing, and the difference in mean plasma concentrations between patients experiencing continuing plasma viral load decline during 2 weeks of VX-950 monotherapy and those experiencing viral rebound is <50% (Chu et al., 2005) . Thus, the substantial boosting expected from ritonavir co-dosing in humans has the potential to both allow more convenient dosing (presumably increasing adherence) and increase efficacy. Ritonavir boosting of HIV PIs has also been demonstrated in multiple clinical studies to create a pharmacological barrier to the development of drug resistance (Eron et al., 2006; Kempf et al., 2004) . Finally, the low doses of ritonavir required for pharmacokinetic boosting (100-200 mg/day) have been widely studied and are well-tolerated in HCV/HIV coinfected patients (Sherman et al., 2005; Sulkowski et al. 2004) . Given the unmet medical need in current HCV therapy, these findings suggest that pharmacokinetic enhancement of HCV PIs with ritonavir in humans should be investigated.
